TY - JOUR T1 - CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD) JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 87-91 LP - 87-91 DO - 10.1111/IGC.0b013e3181c16ba1 VL - 20 IS - 1 AU - Ana Oaknin AU - Pilar Barretina AU - Xavier Pérez AU - Laura Jimenez AU - Montserrat Velasco AU - Maria Alsina AU - Joan Brunet AU - Josep Ramon GermÀ AU - Miguel Beltran Y1 - 2010/01/01 UR - http://ijgc.bmj.com/content/20/1/87-91.abstract N2 - Introduction: In recurrent ovarian cancer, CA-125 could be the only objective response criteria. This study analyzes response patterns regarding CA-125 in responders versus nonresponders and determines whether a specific cutoff value for CA-125 could predict clinical response, compared with response evaluation criteria in solid tumors, in patients receiving pegylated liposomal doxorubicin (PLD).Methods: Sixty-eight patients were identified, 78% were platinum resistant. Relative changes in CA-125 values were calculated, and response was defined as higher than 50% reduction in CA-125 from baseline. Receiver operating characteristic (ROC) curves were constructed based on CA-125 value after the first cycle of PLD to evaluate the most precise cutoff point for the decision model predicting response.Results: Fifty-three patients were assessable for response: 16 patients responded and 37 did not; the median increase of CA-125 was 0.20 (−63; 312) and 52 (−29; 620), respectively. Our ROC curve generated a cutoff value with a sensitivity of 35% (positive test, the proportion of patients who will not respond) and a predictive positive value of 80%. According to the predictive positive value, 20% of the responder patients will be identified as nonresponders; P = 0.025.Conclusions: Our ROC analysis did not demonstrate any reliable CA-125 cutoff on response. Discontinuation of the therapy before cycle 3 may exclude some patients who will benefit from PLD. ER -